Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs

Lisa R. Bartner, Stephanie McGrath, Sangeeta Rao, Linda K. Hyatt, Luke Anthony Wittenburg

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.

Original languageEnglish (US)
Pages (from-to)178-183
Number of pages6
JournalCanadian Journal of Veterinary Research
Volume82
Issue number3
StatePublished - Jul 1 2018

Fingerprint

cannabidiol
Cannabidiol
pharmacokinetics
Pharmacokinetics
Dogs
dogs
mouth
Oils
dosage
oils
methodology
cream
half life
Half-Life
Research

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. / Bartner, Lisa R.; McGrath, Stephanie; Rao, Sangeeta; Hyatt, Linda K.; Wittenburg, Luke Anthony.

In: Canadian Journal of Veterinary Research, Vol. 82, No. 3, 01.07.2018, p. 178-183.

Research output: Contribution to journalArticle

Bartner, Lisa R. ; McGrath, Stephanie ; Rao, Sangeeta ; Hyatt, Linda K. ; Wittenburg, Luke Anthony. / Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. In: Canadian Journal of Veterinary Research. 2018 ; Vol. 82, No. 3. pp. 178-183.
@article{4a75a1e9b3dd498c9bf7fbeedad8c691,
title = "Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs",
abstract = "The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.",
author = "Bartner, {Lisa R.} and Stephanie McGrath and Sangeeta Rao and Hyatt, {Linda K.} and Wittenburg, {Luke Anthony}",
year = "2018",
month = "7",
day = "1",
language = "English (US)",
volume = "82",
pages = "178--183",
journal = "Canadian Journal of Veterinary Research",
issn = "0830-9000",
publisher = "Canadian Veterinary Medical Association",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs

AU - Bartner, Lisa R.

AU - McGrath, Stephanie

AU - Rao, Sangeeta

AU - Hyatt, Linda K.

AU - Wittenburg, Luke Anthony

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.

AB - The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.

UR - http://www.scopus.com/inward/record.url?scp=85050011153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050011153&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 178

EP - 183

JO - Canadian Journal of Veterinary Research

JF - Canadian Journal of Veterinary Research

SN - 0830-9000

IS - 3

ER -